EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Patient Experience Survey Of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

Nancy Holekamp, Brittany Gentile, Audrey Giocanti-Aurégan, Alfredo García-Layana, Tunde Peto, Francesco Viola, Peter J Kertes, Mirela Mirt, Aachal Kotecha, Jeremy Lambert, Hannah B Lewis, Gloria C Chi

Ophthalmic Research · 2024

DOI: 10.1159/000538975 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmic Research, 2024. Verfasst von Nancy Holekamp und 11 weiteren Autor:innen. Beteiligte Einrichtung: Director of Retina Services, Pepose Vision Institute Chesterfield, Chesterfield, Missouri, USA. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Macular Edema, Diabetic Retinopathy, Visual Acuity. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Understanding patient perspectives of treatment may improve adherence and outcomes. This study explored real-world patient experiences with anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

Methods

This multinational, non-interventional, quantitative, cross-sectional, observational survey assessed treatment barriers/burden, patient-reported visual functioning, and treatment satisfaction in DME and nAMD patients in the United States, United Kingdom, Canada, France, Italy, and Spain. Treatment patterns and visual outcomes were extracted from medical charts. Regression models evaluated relationships between adherence, total missed visits, number of anti-VEGF injections and clinical and patient-reported outcomes for visual functioning. Association between treatment satisfaction and aspects of burden were assessed.

Results

The survey was completed by 183 DME and 391 nAMD patients. Patients had moderately high vision-related functioning (25-item National Eye Institute Visual Functioning Questionnaire score: mean=74.8) and were satisfied with their current treatment (mean total score: Macular Disease Treatment Satisfaction Questionnaire=59.2; Retinopathy Treatment Satisfaction Questionnaire=61.3). Treatment satisfaction scores were worse with higher time-related impacts of treatment (nAMD/DME), higher impacts on finances and daily life (nAMD), negative impact on employment and lower expectations for treatment effectiveness (DME). Most patients reported ≥1 barrier (66.1% DME, 49.2% nAMD patients) related to treatment (35.0%), clinic (32.6%), and COVID-19 (21.1%). Moreover, 44.9% of patients reported some impairment in activities of daily living. Work absenteeism was observed among >60% of working patients. Nearly one-quarter (24.2%) of patients needed ≥1 day to recover from intravitreal injections; most reported ≥30 minutes of travel time (73.7%) and clinic wait time (54.2%). In unadjusted univariable analyses, treatment adherence (vs non adherence) was related to higher most recent visual acuity (β = 8.98 letters; CI, 1.34–16.62) and lower odds of visual acuity below driving vision (≤ 69 letters) (OR = 0.50; CI, 0.25–1.00) .

Conclusion

More durable treatments with reduced frequency of injections/visits may reduce treatment burden and improve patient satisfaction, which may enhance adherence and visual outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsMacular EdemaDiabetic RetinopathyVisual AcuityIntravitreal InjectionsVascular Endothelial Growth Factor AWet Macular DegenerationPatient SatisfactionHumansMaleFemaleCross-Sectional StudiesAgedSurveys and QuestionnairesRanibizumabMiddle AgedAged, 80 and overTomography, Optical CoherenceBevacizumabTreatment Outcome

Stichwörter der Autor:innen

Anti-vascular endothelial growth factor injectionsDiabetic macular edemaNeovascular age-related macular degenerationQuantitative surveyTreatment adherenceTreatment burden

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabBevacizumab

Autor:innen und Institutionen

  • Director of Retina Services, Pepose Vision Institute Chesterfield, Chesterfield, Missouri, USA.
  • Genentech, South San Francisco, California, USA.
  • Ophthalmology Department, Avicenne Hospital, Sorbonne Paris Nord University, Bobigny, France.
  • Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
  • Queen's University Belfast, Belfast, UK.
  • Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Zitieren

APA

Holekamp, N., Gentile, B., Giocanti-Aurégan, A., García-Layana, A., Peto, T., Viola, F., Kertes, P. J., Mirt, M., Kotecha, A., Lambert, J., Lewis, H. B., & Chi, G. C. (2024). Patient Experience Survey Of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmic Research. https://doi.org/10.1159/000538975

Vancouver

Holekamp N, Gentile B, Giocanti-Aurégan A, García-Layana A, Peto T, Viola F, et al. Patient Experience Survey Of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmic Research. 2024. doi:10.1159/000538975

BibTeX
@article{Holekamp2024,
  author = {Holekamp, Nancy and Gentile, Brittany and Giocanti-Aurégan, Audrey and García-Layana, Alfredo and Peto, Tunde and Viola, Francesco and Kertes, Peter J and Mirt, Mirela and Kotecha, Aachal and Lambert, Jeremy and Lewis, Hannah B and Chi, Gloria C},
  title = {Patient Experience Survey Of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema},
  journal = {Ophthalmic Research},
  year = {2024},
  doi = {10.1159/000538975}
}
Kostenlos starten →